Impact of frequent cerebrospinal fluid sampling on Aβ levels: Systematic approach to elucidate influencing factors

Alzheimer's Research and Therapy

Volumn 8, Issue 1, 2016, Pages

  Van Broeck, Bianca ^a   Timmers, Maarten ^a,e   Ramael, Steven ^b   Bogert, Jennifer ^c   Shaw, Leslie M ^d   Mercken, Marc ^a   Slemmon, John ^c   Van Nueten, Luc ^a   Engelborghs, Sebastiaan ^e,f   Streffer, Johannes Rolf ^a,e  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b SGS Life Science Services   (Belgium)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF ANTWERP   (Belgium)

^f ZNA Hospital Network Antwerp   (Belgium)

Author keywords

Alzheimer's disease; A peptides; Catheterization; Cerebrospinal fluid; Sampling frequency

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-37]; AMYLOID BETA PROTEIN[1-38]; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E EPSILON 4; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; IBUPROFEN; TAU PROTEIN; UNCLASSIFIED DRUG; AMYLOID BETA-PROTEIN (1-42); MAPT PROTEIN, HUMAN; PEPTIDE FRAGMENT;

ADULT; AGE DISTRIBUTION; AGED; APPLICATION SITE PAIN; ARTICLE; BACKACHE; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATOPHYTOSIS; FEMALE; GASTROESOPHAGEAL REFLUX; HEADACHE; HOT FLUSH; HUMAN; HYPESTHESIA; LIMB PAIN; MALE; NAUSEA; NECK PAIN; PATIENT SAFETY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; PRURITUS; SEX DIFFERENCE; SINUSITIS; TOOTH PAIN; CATHETERIZATION; CEREBROSPINAL FLUID; INDWELLING CATHETER; LUMBAR PUNCTURE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; BIOMARKERS; CATHETERIZATION; CATHETERS, INDWELLING; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; SPINAL PUNCTURE; TAU PROTEINS;

EID: 84969535735     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/s13195-016-0184-z     Document Type: Article

References (25)

1. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6:131-44.
2. Blennow K, Zetterberg H, Fagan AM. Fluid biomarkers in Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2:a006221.
3. Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, et al. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol. 2009;66:48-54.
4. Li J, Llano DA, Ellis T, LeBlond D, Bhathena A, Jhee SS, et al. Effect of human cerebrospinal fluid sampling frequency on amyloid-beta levels. Alzheimers Dement. 2012;8:295-303.
5. Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology. 2007;68:666-9.
6. Forman M, Palcza J, Tseng J, Leempoels J, Ramael S, Han D, et al. The novel BACE inhibitor MK-8931 dramatically lowers cerebrospinal fluid Aβ peptides in healthy subjects following single- and multiple-dose administration. Alzheimers Dement. 2012;8(4):704.
7. Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, et al. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009;326:1005-7.
8. Slats D, Claassen JA, Spies PE, Borm G, Besse KT, van Aalst W, et al. Hourly variability of cerebrospinal fluid biomarkers in Alzheimer's disease subjects and healthy older volunteers. Neurobiol Aging. 2012;33:831. e1-9.
9. Tong G, Castaneda L, Wang JS, Sverdlov O, Huang SP, Slemmon R, et al. Effects of single doses of avagacestat (BMS-708163) on cerebrospinal fluid Abeta levels in healthy young men. Clin Drug Investig. 2012;32:761-9.
10. Verwey NA, van der Flier WM, Blennow K, Clark C, Sokolow S, De Deyn PP, et al. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Ann Clin Biochem. 2009;46:235-40.
11. Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, et al. CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement. 2013;9:251-61.
12. Florkowski CM. Preanalytical variables and Alzheimer disease biomarker concentrations in cerebrospinal fluid. Clin Chem. 2015;61:686-88.
13. Le Bastard N, De Deyn PP, Engelborghs S. Importance and impact of preanalytical variables on Alzheimer disease biomarker concentrations in cerebrospinal fluid. Clin Chem. 2015;61:734-43.
14. 1-37/38/40/42 levels after treatment with secretase inhibitors and modulators using a novel immunoassay. Neurodegener Dis. 2013;11.
15. Struyfs H, Van Broeck B, Timmers M, Fransen E, Sleegers K, Van Broeckhoven C, et al. Diagnostic accuracy of CSF amyloid-β isoforms for early and differential dementia diagnosis. J Alzheimers Dis. 2015;45:813-22.
16. 42. Neurobiol Aging. 2000;21:S41.
17. Shaw LM, Vanderstichele H, Knapik-Czajka M, Figurski M, Coart E, Blennow K, et al. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol. 2011;121:597-609.
18. 1-42. Alzheimers Dement. 2014;10:P811.
19. Favis R, Gerry NP, Cheng YW, Barany F. Applications of the universal DNA microarray in molecular medicine. Methods Mol Med. 2005;114:2-58.
20. Imbimbo BP, Giardina GA. γ-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes. Curr Top Med Chem. 2011;11:1555-70.
21. 42 independently of cyclooxygenase activity. Nature. 2001;414:212-16.
22. Blennow K, Zetterberg H, Minthon L, Lannfelt L, Strid S, Annas P, et al. Longitudinal stability of CSF biomarkers in Alzheimer's disease. Neurosci Lett. 2007;419:18-22.
23. Zetterberg H, Pedersen M, Lind K, Svensson M, Rolstad S, Eckerström C, et al. Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. J Alzheimers Dis. 2007;12:255-60.
24. Bissette G. Does Alzheimer's disease result from attempts at repair or protection after transient stress? J Alzheimers Dis. 2009;18:371-80.
25. Huang Y, Potter R, Sigurdson W, Santacruz A, Shih S, Ju YE, et al. Effects of age and amyloid deposition on Aβ dynamics in the human CNS. Arch Neurol. 2012;69:51-8.